Characterising the urinary acylcarnitine and amino acid profiles of HIV/TB co-infection, using LC-MS metabolomics.
Charles PretoriusLaneke LuiesPublished in: Metabolomics : Official journal of the Metabolomic Society (2024)
The metabolic profiling of HIV/TB co-infection highlights the profound impact of TB on metabolic pathways, which may exacerbate the clinical complexities of co-infection. Understanding these metabolic disruptions can guide the development of targeted treatments and improve management strategies, ultimately enhancing the clinical outcomes for these patients. Further research is required to validate these findings and explore their implications in larger, diverse populations.
Keyphrases
- antiretroviral therapy
- mycobacterium tuberculosis
- hiv positive
- hiv infected
- human immunodeficiency virus
- end stage renal disease
- hiv testing
- hepatitis c virus
- hiv aids
- amino acid
- ejection fraction
- chronic kidney disease
- newly diagnosed
- men who have sex with men
- prognostic factors
- intellectual disability
- cancer therapy
- autism spectrum disorder
- genetic diversity